Psychedelics: Real risk or human right? Harvard Law panel weighs medical evidence, human rights, and access barriers for illegal hallucinogens

Psychedelics policy depends on whether the key problem is real safety risk or a rights-based harm from prohibition. A Harvard Law School panel framed the debate around how to balance dangers that rise outside medical contexts with the need to expand research and access. Speakers contrasted the case for rigorous clinical study of classic psychedelics like LSD, psilocybin, and DMT with arguments that drug enforcement and prohibition can produce broader social harms. Cat Packer emphasized human rights and linked drug policy to structural harms, while David Yaden argued that inherent risks exist and that better medical research is needed but constrained by illegality. The panel also addressed lived experience and medical-approval standards. A veteran described ibogaine as transformative for post-traumatic stress disorder and argued that restricting access would amount to religious discrimination, while a medical ethics and law professor cautioned that regulators like the FDA rely on medically grounded evidence. The discussion noted ongoing clinical development, including phase-three work on synthetic psilocybin by Compass, and highlighted tension within the psychedelic community over the right pathway forward.